Haraguchi Toshiaki, Miyoshi Hiroaki, Hiraoka Koji, Yokoyama Shintaro, Ishibashi Yukinao, Hashiguchi Toshihiro, Matsuda Koutaro, Hamada Tetsuya, Okawa Takahiro, Shiba Naoto, Ohshima Koichi
Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Department of Orthopedic Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
PLoS One. 2016 Jun 1;11(6):e0156524. doi: 10.1371/journal.pone.0156524. eCollection 2016.
Recent studies have investigated the significance of GATA3 expression in patients with various malignant tumors. However, no previous studies have evaluated the clinicopathological importance of GATA3 expression in soft tissue sarcomas (STS) patients.
We evaluated GATA3 expression in 76 STS cases using immunohistochemical analysis, and statistically compared clinicopathological characteristics between GATA3-positive and GATA3-negative cases.
GATA3-positive expression was significantly associated with a higher mitotic count (P < 0.0001). Disease-free survival (DFS) of GATA3-positive cases was significantly shorter than that of cases without GATA3 expression (P = 0.0104). Overall survival (OS) of GATA3-positive cases was significantly shorter than that of cases without GATA3 expression (P = 0.0006). GATA3-positive expression was significantly associated with shorter DFS in both univariate analysis (hazard ratio [HR], 2.719; P = 0.012) and multivariate analysis (HR, 2.711; P = 0.014). GATA3-positive expression was also significantly associated with worse OS in both univariate analysis (HR, 5.730; P = 0.0007) and multivariate analysis (HR, 5.789; P = 0.0008).
These results indicate that GATA3 is an independent prognostic factor and suggest that evaluation of GATA3 expression might enable more effective clinical follow-up using prognostic stratification of STS patients.
近期研究探讨了GATA3表达在各种恶性肿瘤患者中的意义。然而，既往尚无研究评估GATA3表达在软组织肉瘤（STS）患者中的临床病理重要性。
我们采用免疫组化分析评估了76例STS病例中的GATA3表达，并对GATA3阳性和GATA3阴性病例的临床病理特征进行了统计学比较。
GATA3阳性表达与较高的有丝分裂计数显著相关（P < 0.0001）。GATA3阳性病例的无病生存期（DFS）显著短于无GATA3表达的病例（P = 0.0104）。GATA3阳性病例的总生存期（OS）显著短于无GATA3表达的病例（P = 0.0006）。在单因素分析（风险比[HR]，2.719；P = 0.012）和多因素分析（HR，2.711；P = 0.014）中，GATA3阳性表达均与较短的DFS显著相关。在单因素分析（HR，5.730；P = 0.0007）和多因素分析（HR，5.789；P = 0.0008）中GATA3阳性表达也均与较差的OS显著相关。
这些结果表明GATA3是一个独立的预后因素，并提示评估GATA3表达可能有助于通过STS患者的预后分层进行更有效的临床随访。
